Nurulain T Zaveri1. 1. Astraea Therapeutics , 320 Logue Avenue, Suite 142, Mountain View, California 94043, United States.
Abstract
In the two decades since the discovery of the nociceptin opioid receptor (NOP) and its ligand, nociceptin/orphaninFQ (N/OFQ), steady progress has been achieved in understanding the pharmacology of this fourth opioid receptor/peptide system, aided by genetic and pharmacologic approaches. This research spawned an explosion of small-molecule NOP receptor ligands from discovery programs in major pharmaceutical companies. NOP agonists have been investigated for their efficacy in preclinical models of anxiety, cough, substance abuse, pain (spinal and peripheral), and urinary incontinence, whereas NOP antagonists have been investigated for treatment of pain, depression, and motor symptoms in Parkinson's disease. Translation of preclinical findings into the clinic is guided by PET and receptor occupancy studies, particularly for NOP antagonists. Recent progress in preclinical NOP research suggests that NOP agonists may have clinical utility for pain treatment and substance abuse pharmacotherapy. This review discusses the progress toward validating the NOP-N/OFQ system as a therapeutic target.
In the two decades since the discovery of the nociceptin opioid receptor (n class="Gene">NOP) and its ligand, nociceptin/orphaninFQ (N/OFQ), steady progress has been achieved in understanding the pharmacology of this fourth opioid receptor/peptide system, aided by genetic and pharmacologic approaches. This research spawned an explosion of small-molecule NOP receptor ligands from discovery programs in major pharmaceutical companies. NOP agonists have been investigated for their efficacy in preclinical models of anxiety, cough, substance abuse, pain (spinal and peripheral), and urinary incontinence, whereas NOP antagonists have been investigated for treatment of pain, depression, and motor symptoms in Parkinson's disease. Translation of preclinical findings into the clinic is guided by PET and receptor occupancy studies, particularly for NOP antagonists. Recent progress in preclinical NOP research suggests that NOP agonists may have clinical utility for pain treatment and substance abuse pharmacotherapy. This review discusses the progress toward validating the NOP-N/OFQ system as a therapeutic target.
Authors: R L McLeod; L E Parra; J C Mutter; C H Erickson; G J Carey; D B Tulshian; A B Fawzi; A Smith-Torhan; R W Egan; F M Cuss; J A Hey Journal: Br J Pharmacol Date: 2001-03 Impact factor: 8.739
Authors: Robbie L McLeod; Deen B Tulshian; Ginny D Ho; Xiomara Fernandez; Donald C Bolser; Leonard E Parra; Jennifer C Zimmer; Christine H Erickson; Ahmad B Fawzi; Huchappa Jayappa; Craig Lehr; Jason Erskine; April Smith-Torhan; Hongtao Zhang; John A Hey Journal: Pharmacology Date: 2009-08-20 Impact factor: 2.547
Authors: Geoffrey B Varty; Sherry X Lu; Cynthia A Morgan; Mary E Cohen-Williams; Robert A Hodgson; April Smith-Torhan; Hongtao Zhang; Ahmad B Fawzi; Michael P Graziano; Ginny D Ho; Julius Matasi; Deen Tulshian; Vicki L Coffin; Galen J Carey Journal: J Pharmacol Exp Ther Date: 2008-05-20 Impact factor: 4.030
Authors: Norikazu Kiguchi; Huiping Ding; Gerta Cami-Kobeci; Devki D Sukhtankar; Paul W Czoty; Heather B DeLoid; Fang-Chi Hsu; Lawrence Toll; Stephen M Husbands; Mei-Chuan Ko Journal: Br J Anaesth Date: 2019-03-01 Impact factor: 9.166
Authors: Huiping Ding; Norikazu Kiguchi; Dennis Yasuda; Pankaj R Daga; Willma E Polgar; James J Lu; Paul W Czoty; Shiroh Kishioka; Nurulain T Zaveri; Mei-Chuan Ko Journal: Sci Transl Med Date: 2018-08-29 Impact factor: 17.956
Authors: Shawn M Flynn; Phillip M Epperly; April T Davenport; Gerta Cami-Kobeci; Stephen M Husbands; Mei-Chuan Ko; Paul W Czoty Journal: Neuropsychopharmacology Date: 2019-04-10 Impact factor: 7.853
Authors: Huiping Ding; Paul W Czoty; Norikazu Kiguchi; Gerta Cami-Kobeci; Devki D Sukhtankar; Michael A Nader; Stephen M Husbands; Mei-Chuan Ko Journal: Proc Natl Acad Sci U S A Date: 2016-08-29 Impact factor: 11.205
Authors: Nurulain T Zaveri; Paul V Marquez; Michael E Meyer; Willma E Polgar; Abdul Hamid; Kabirullah Lutfy Journal: Alcohol Clin Exp Res Date: 2018-01-19 Impact factor: 3.455